Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome, M. Sasso, Jonathan J Deeks, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 4, pp. 362-373
Open Access | Times Cited: 586

Showing 1-25 of 586 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1810
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1135
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1116
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter, Mary E. Rinella
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1851-1864
Closed Access | Times Cited: 984
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 637
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 372
Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby, Emmanuel L. Gautier
Nature reviews. Immunology (2021) Vol. 22, Iss. 7, pp. 429-443
Open Access | Times Cited: 372
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Ferenc E. Mózes, Jenny Lee, Emmanuel Selvaraj, et al.
Gut (2021) Vol. 71, Iss. 5, pp. 1006-1019
Open Access | Times Cited: 357
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 331
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
Emmanuel Selvaraj, Ferenc E. Mózes, Arjun Jayaswal, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 770-785
Open Access | Times Cited: 233
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 205
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
Emir Muzurović, Dimitri P. Mikhailidis, Christos S. Mantzoros
Metabolism (2021) Vol. 119, pp. 154770-154770
Closed Access | Times Cited: 195
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
David Petroff, Valentin Blank, Philip N. Newsome, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 3, pp. 185-198
Open Access | Times Cited: 192
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Michelle T. Long, Mazen Noureddin, Joseph K. Lim
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 764-774.e1
Open Access | Times Cited: 181
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
Archives of Medical Research (2020) Vol. 52, Iss. 1, pp. 25-37
Closed Access | Times Cited: 165
Imaging biomarkers of NAFLD, NASH, and fibrosis
Veeral Ajmera, Rohit Loomba
Molecular Metabolism (2021) Vol. 50, pp. 101167-101167
Open Access | Times Cited: 150
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 147
Current therapies and new developments in NASH
Jean‐François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2123-2134
Open Access | Times Cited: 146
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint, Grit Andersen, Paul Hockings, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1150-1161
Open Access | Times Cited: 143
Nonalcoholic fatty liver disease: another leap forward
Manal F. Abdelmalek
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 2, pp. 85-86
Open Access | Times Cited: 142
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 607-618
Open Access | Times Cited: 142
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Mazen Noureddin, Emily Truong, Jeffrey Gornbein, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 781-787
Closed Access | Times Cited: 132
Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
Piotr Dobrowolski, Aleksander Prejbisz, Alina Kuryłowicz, et al.
Archives of Medical Science (2022) Vol. 18, Iss. 5, pp. 1133-1156
Open Access | Times Cited: 127
Page 1 - Next Page

Scroll to top